Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer

[1]  Evis Sala,et al.  Imaging breast cancer using hyperpolarized carbon-13 MRI , 2020, Proceedings of the National Academy of Sciences.

[2]  E. de Azambuja,et al.  Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Bernards,et al.  POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients , 2019, Clinical Cancer Research.

[4]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[5]  C. Arteaga,et al.  Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. , 2019, Cancer discovery.

[6]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[7]  C. Toulas,et al.  FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker , 2018, Oncotarget.

[8]  E. White,et al.  FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis , 2018, The Journal of clinical investigation.

[9]  L. Pusztai,et al.  Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer , 2018, Clinical Cancer Research.

[10]  Shu-Ming Sun,et al.  FoxM1 is a promising candidate target in the treatment of breast cancer , 2017, Oncotarget.

[11]  E. Lam,et al.  The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance , 2017, Seminars in cancer biology.

[12]  David Haussler,et al.  The UCSC Genome Browser database: 2018 update , 2017, Nucleic Acids Res..

[13]  Harry W. Clifford,et al.  Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts , 2018, BMC Genomics.

[14]  Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study , 2017, Breast Cancer Research.

[15]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[16]  L. Penn,et al.  MYC Deregulation in Primary Human Cancers , 2017, Genes.

[17]  J. Baselga,et al.  Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. , 2017, Cancer discovery.

[18]  A. Rodríguez-Ariza,et al.  The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis , 2017, Oncotarget.

[19]  Kevin M. Brindle,et al.  Single shot three‐dimensional pulse sequence for hyperpolarized 13C MRI , 2016, Magnetic resonance in medicine.

[20]  L. Garraway,et al.  Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. , 2016, Cancer discovery.

[21]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[22]  W. Cui,et al.  Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination , 2016, Development.

[23]  S. Chandarlapaty,et al.  PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition , 2016, Cancer cell.

[24]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[25]  E. Lam,et al.  Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance , 2016, Current drug targets.

[26]  J. Albeck,et al.  Phosphoinositide 3-Kinase regulates glycolysis through mobilization of Aldolase A from the actin cytoskeleton , 2014, Cancer & Metabolism.

[27]  P. Nunn,et al.  The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor , 2015, Brain pathology.

[28]  B. Vanderhyden,et al.  Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression , 2015, Oncotarget.

[29]  H. Esumi,et al.  Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma , 2015, The Journal of Biological Chemistry.

[30]  Michael G. Kharas,et al.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.

[31]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[32]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[33]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[34]  J. Engelman,et al.  Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.

[35]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[36]  Michael V. Gormally,et al.  Suppression of the FOXM1 transcriptional program via novel small molecule inhibition , 2014, Nature Communications.

[37]  Suyun Huang,et al.  FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression , 2014, Clinical Cancer Research.

[38]  S. Nada,et al.  The mTOR Pathway Controls Cell Proliferation by Regulating the FoxO3a Transcription Factor via SGK1 Kinase , 2014, PloS one.

[39]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[40]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[41]  G. Hampton,et al.  Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer , 2013, Oncogenesis.

[42]  Martin O. Leach,et al.  Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized 13C Magnetic Resonance Spectroscopy Data , 2013, PloS one.

[43]  R. Pearson,et al.  AKT-independent PI3-K signaling in cancer – emerging role for SGK3 , 2013, Cancer management and research.

[44]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[45]  N. Rosen,et al.  mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.

[46]  Steve Price,et al.  Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. , 2013, Journal of medicinal chemistry.

[47]  Arto Mannermaa,et al.  Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors , 2013, Molecular and Cellular Endocrinology.

[48]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[49]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[50]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[51]  C. James,et al.  Reduced Phosphocholine and Hyperpolarized Lactate Provide Magnetic Resonance Biomarkers of Pi3k/akt/mtor Inhibition in Glioblastoma Neuro-onco Lo Gy , 2022 .

[52]  D. Vignali,et al.  Design and construction of 2A peptide-linked multicistronic vectors. , 2012, Cold Spring Harbor protocols.

[53]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[54]  E. Lam,et al.  FOXM1: From cancer initiation to progression and treatment. , 2012, Biochimica et biophysica acta.

[55]  S. Gygi,et al.  A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.

[56]  G. Tzivion,et al.  FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. , 2011, Biochimica et biophysica acta.

[57]  K. Brindle,et al.  Kinetic Modeling of Hyperpolarized 13C Label Exchange between Pyruvate and Lactate in Tumor Cells* , 2011, The Journal of Biological Chemistry.

[58]  S. Chandarlapaty,et al.  PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer , 2011, Oncogene.

[59]  Rebekah McLaughlin,et al.  Magnetization transfer measurements of exchange between hyperpolarized [1‐13C]pyruvate and [1‐13C]lactate in a murine lymphoma , 2010, Magnetic resonance in medicine.

[60]  John Kurhanewicz,et al.  Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Cancer research.

[61]  Johan Hartman,et al.  FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance , 2010, Oncogene.

[62]  M. Belvin,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. , 2010, Cancer research.

[63]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[64]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[65]  J. D. Benson,et al.  Single-vector inducible lentiviral RNAi system for oncology target validation , 2009, Cell cycle.

[66]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[67]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[68]  Kevin Brindle,et al.  New approaches for imaging tumour responses to treatment , 2008, Nature Reviews Cancer.

[69]  A. Brunet,et al.  FOXO transcription factors , 2007, Current Biology.

[70]  R. Chibbar,et al.  Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen , 2005, Modern Pathology.

[71]  Robert H. Costa,et al.  Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators , 2004, Molecular and Cellular Biology.

[72]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[73]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.